Eftilagimod alpha

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Retrieved on: 
Thursday, December 7, 2023
Immunotherapy, Recherche, ASX, Research, European, IMM, Cancer, Calendar, CIR, Immutep, Eftilagimod alpha

SYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).

Key Points: 
  • The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
  • Immutep qualifies for the CIR tax incentive through its subsidiary Immutep S.A.S.
  • Immutep also qualifies for cash rebates from the Australian Federal Government’s R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.
  • As previously announced, in October 2023, the company received an A$1.13 million cash rebate from the Australian Federal Government’s R&D tax incentive program for the eligible R&D activities conducted in financial year 2022.

Immutep Completes A$80 Million Capital Raise

Retrieved on: 
Tuesday, June 27, 2023
Cancer, Lung cancer, Head, ASX, Phase 3, IMM, US, Autoimmune disease, Immune system, Eftilagimod alpha, Pharmaceutical industry, Vaccine, Immutep

SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces the successful completion of an A$80 million capital raise to support its late-stage and expanding clinical development pipeline. With this new capital, Immutep believes it is fully funded for its current and expanded clinical program through to Q1 CY2026 with a pro-forma cash balance of A$135.2 million (US$90.6 million).1

Key Points: 
  • SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces the successful completion of an A$80 million capital raise to support its late-stage and expanding clinical development pipeline.
  • With this new capital, Immutep believes it is fully funded for its current and expanded clinical program through to Q1 CY2026 with a pro-forma cash balance of A$135.2 million (US$90.6 million).1
    Dr. Russell Howard, Chairman of Immutep, said, “These funds will help us further our mission to unlock the power of the immune system to fight cancer and autoimmune disease, including advancing eftilagimod alpha into a new registrational Phase III trial in lung cancer, and supporting its late-stage trials in head and neck cancer and metastatic and triple negative breast cancer, to final data and Phase II read-outs, respectively.
  • We’ll also be able to expand eftilagimod alpha into new settings and potentially conduct a first-in-human Phase I trial for IMP761, the world’s first and only LAG-3 agonist, for autoimmune diseases.
  • Our path forward has never been so exciting.”

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
LAG-3, START, Progression-free survival, Survival, MHC, Cancer, Platinum, ASX, Teaching hospital, Fast track (FDA), ASCO, Patient, CPS, HNSCC, Merck, Merck & Co., Pembrolizumab, Poster, Eftilagimod alpha, Merck Sharp & Dohme Federal Credit Union, PD-L1, Pharmaceutical industry

SYDNEY, AUSTRALIA, June 05, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today provides an overview of the positive final data from Part C of the TACTI-002 Phase II trial to be presented in a poster presentation at the ASCO 2023 Annual Meeting taking place in Chicago, US.

Key Points: 
  • Notably, one of the five complete responses that lasted 28 months (as of the data cut-off) occurred in a patient with negative PD-L1 expression or CPS
  • The safety profile of efti in combination with pembrolizumab continues to be safe and very well tolerated.
  • "These final results in 2nd line HNSCC are very encouraging in a difficult to treat patient population.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

Retrieved on: 
Monday, May 1, 2023
Carcinoma, MHC, Cancer, Paul Ehrlich Institute, Merck Group, Bladder cancer, ASX, B cell, Cell, Transitional cell carcinoma, IMM, National Cancer Institute, Death, MHC class II, Patient, Autoimmune disease, Research, Vaccine, Eftilagimod alpha, PD-L1, Avelumab, Safety, Transitional epithelium, Pharmaceutical industry, Biomedicine

SYDNEY, AUSTRALIA, May 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory approval from the Paul-Ehrlich-Institut (“PEI”), German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha (“efti”) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma.

Key Points: 
  • Urothelial carcinoma is the most common type of bladder cancer.
  • “We are excited to get this important trial underway.
  • Encouragingly, deep and durable responses were achieved in patients with low or negative PD-L1 expression as well as immuno-oncology insensitive tumours.
  • INSIGHT currently consists of 5 different arms from stratums A to E (INSIGHT-005 is Stratum E).

Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Abstract, LAG-3, START, Cancer, Paclitaxel, Head, ASX, Part, Neck, Teaching hospital, MD Anderson Cancer Center, ASCO, IMM, Patient, Division, University, Autoimmune disease, Annual general meeting, Phase, Pembrolizumab, Eftilagimod alpha, Society, PD-L1, Pharmaceutical industry

SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces two abstracts have been selected for poster presentation at the upcoming 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 2-6 June 2023 in Chicago, Illinois (United States).

Key Points: 
  • SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces two abstracts have been selected for poster presentation at the upcoming 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 2-6 June 2023 in Chicago, Illinois (United States).
  • New, final data from Part C of the Phase II TACTI-002 trial evaluating the investigational dual immuno-oncology combination of eftilagimod alpha and pembrolizumab in 2nd line head and neck squamous cell carcinoma patients unselected for PD-L1 expression will be presented.
  • In addition, the Phase II/III AIPAC-003 trial design will be presented in a Trial-in-Progress Poster.
  • Presenter: Dr. Nuhad K. Ibrahim, Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Triumvira Immunologics Presents Promising Data on TAC T Cells for the Treatment of HER2-overexpressing Solid Tumors at the 2023 AACR Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Abstract (summary), AACR, Therapy, HER2, Cancer, Toxicity, Eftilagimod alpha, TAC, CD8, Patient, Mouse, Neoplasm, CD4, T, White, Safety, Pharmaceutical industry, Medical imaging, Vaccine

The presentations will include updated clinical data from the ongoing TACTIC-2 trial of TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.

Key Points: 
  • The presentations will include updated clinical data from the ongoing TACTIC-2 trial of TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.
  • TAC01-HER2 obtained a disease control rate of 67% in heavily pretreated patients with solid tumors in patients who failed all standard of care therapies.
  • In a 5-day in vitro potency assay, patient-derived products showed effective tumor cell killing response similar to healthy-donor derived TAC T cells.
  • HER2-TAC γδ (gamma/delta) T cells selectively react to and kill HER2-expressing tumor cells in co-culture at low effector-to-target ratios, indicating strong functionality.

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

Retrieved on: 
Friday, March 31, 2023
War, Immunology, Doctor of Philosophy, DCR, Overalls, Survival, MHC, OS, Cancer, TGK, Head, ASX, Oncology, B cell, NSCLC, CMO, Part, Lung cancer, ELCC, PFS, TPS, IMM, Neoplasm, Monocyte, All-comers track meet, Patient, Autoimmune disease, Immutep, Acceleration, Hospital, APC, PD-1, MOS, Pembrolizumab, Eftilagimod alpha, Poster, ORR, Kinetics, Medical imaging, Palladium, Pharmaceutical industry, Vaccine

SYDNEY, AUSTRALIA, March 31, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive final data from Part B of the TACTI-002 Phase II trial in 2nd line metastatic non-small cell lung cancer (NSCLC) patients refractory to anti-PD-(L)1 therapy via a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023.

Key Points: 
  • This unique stimulation of antigen-presenting cells (APC) leads to a broad anti-tumour immune response, and the addition of efti to pembrolizumab may help refractory 2nd line NSCLC patients that have few therapeutic options by reverting their anti-PD-(L)1 resistance.
  • The ORR, PFS, and OS were more pronounced in patients with high PD-L1 expression (N=6) or who were secondary resistant (N=25).
  • For patients with ≥50% PD-L1 TPS expression, mOS was not yet reached, ORR was 33.3%, and 6-month PFS was 50%.
  • Efti plus pembrolizumab was well tolerated without any new safety signals, and there was no treatment discontinuation due to adverse reactions.

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

Retrieved on: 
Thursday, March 23, 2023
Cancer, ASX, NSCLC, ELCC, IMM, Patient, CEST, Autoimmune disease, Pembrolizumab, Eftilagimod alpha, Poster, Pharmaceutical industry, Part

SYDNEY, AUSTRALIA, March 23, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that new data evaluating eftilagimod alpha in combination with pembrolizumab from Part B of the TACTI-002 Phase II trial in 2nd line PD-X refractory non-small cell lung cancer (NSCLC) patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023 taking place in Copenhagen, Denmark and virtually from 29 March to 1 April 2023.

Key Points: 
  • The PD-X refractory, NSCLC patients in Part B of the TACTI-002 Phase II trial represent a difficult-to-treat patient population.
  • All enrolled patients (N=36) had confirmed progression (i.e., two consecutive scans) after standard of care 1st line treatment with anti-PD-X therapy including a majority that received anti-PD-X therapy and chemotherapy.
  • The abstract (#11MO) will be available here on the ELCC 2023 website.
  • The related Mini Oral Presentation with new and updated final data that are not part of the abstract will made available on 31 March 2023 at 08:25AM, CEST and will subsequently be posted on the Posters & Publications section of Immutep’s website.

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, October 4, 2022
MHC II, Solution, APC, HNSCC, Cancer, GLOBE, MHC, Eftilagimod alpha, NASDAQ, CD8, Monocyte, Annual general meeting, Review, ASCO, Technology, Immunotherapy, Australian Securities Exchange, Immunology, IMM, CEO, LAG-3, Macrophage, Accelerated approval (FDA), Head, FDA, Antibody, ASX, Fast track (FDA), Immune system, Priority review, Large-cell lung carcinoma, Autoimmune disease, Patient, Fast Track, NSCLC, PD-L1, B cell, Society, Pembrolizumab, White Light Rock & Roll Review, Company, Antigen, Vaccine, Pharmaceutical industry, Immutep

We are pleased to receive this Fast Track designation as it acknowledges eftis unique potential to empower the human immune system against cancer and significantly enhance patient responses to standard-of-care immunotherapy.

Key Points: 
  • We are pleased to receive this Fast Track designation as it acknowledges eftis unique potential to empower the human immune system against cancer and significantly enhance patient responses to standard-of-care immunotherapy.
  • Efti also offers a chemotherapy-free option for NSCLC patients in need of less toxic and more durable solutions, stated Marc Voigt, CEO of Immutep.
  • Efti is under evaluation for a variety of solid tumors including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and HER2/HR+ metastatic breast cancer.
  • Efti has received Fast Track Designation in 1st line recurrent or metastatic HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA).

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

Retrieved on: 
Friday, September 23, 2022
ASX, Eftilagimod alpha, Autoimmune disease, French Government of the Hundred Days, CIR, Infection, Australian Securities Exchange, Antibody, Calendar, Immunotherapy, IMM, Patient, Cancer, Technology, Immutep, Recherche, Degenerative disease, 2009 Australian federal budget, LAG-3, NASDAQ, Research, GLOBE, R, Union, APC, Health insurance, Vaccine

The Crdit dImpt Recherche (CIR), meaning Research Tax Credit, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.

Key Points: 
  • The Crdit dImpt Recherche (CIR), meaning Research Tax Credit, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
  • Immutep qualifies to receive the CIR tax incentive through its subsidiary Immutep S.A.S.
  • Immutep also qualifies for cash rebates from the Australian Federal Governments R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.